We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Women with Gestational Diabetes Need Retesting After Pregnancy

By LabMedica International staff writers
Posted on 12 May 2010
Women who have had gestational diabetes should be retested for diabetes 6 to 12 weeks after the baby is born, and at least every three years after that. Follow-up screening usually consists of a simple blood test.

Generally, steps are taken to manage gestational diabetes during pregnancy for the health of both mother and child. However, many women do not realize that if they have had gestational diabetes they are at increased risk for developing diabetes in the future, and their child is also at increased risk for obesity and type 2 diabetes.

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; Bethesda MD, USA) and the Office of Research on Women's Health (ORWH; Bethesda, MD, USA) are together promoting awareness of risks attached for mothers and children after pregnancies where there had been gestational diabetes. A special effort was made from May 9-15, 2010, which included Mother's Day in many parts of the world, and [US] National Women's Health Week.

"Many women think that if the follow-up test after the baby is born shows no signs of diabetes, they are in the clear, but that is not the case," said Vivian Pinn, M.D., director of the ORWH. "What many of these moms do not know is that they have a 40 % to 60 % chance of developing diabetes as early as five to 10 years after their baby is born. These women need to know this information and they need to take steps to lower their risk for developing diabetes."

Related Links:
U.S. National Institute of Diabetes and Digestive and Kidney Diseases
Office of Research on Women's Health



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS

Latest Clinical Chem. News

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
12 May 2010  |   Clinical Chem.

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
12 May 2010  |   Clinical Chem.

Low-Cost Portable Screening Test to Transform Kidney Disease Detection
12 May 2010  |   Clinical Chem.